Breaking News, Collaborations & Alliances

AffyXell Expands Manufacturing Partnership with GenScript ProBio

Will develop next generation cell and gene therapies based on mesenchymal stem cells which incorporate Affimer immunotherapies.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Avacta Group, a clinical stage oncology drug company developing cancer therapies, said that AffyXell, its joint venture with South Korean drug maker Daewoong Pharmaceutical, has expanded its partnership with GenScript ProBio, a biopharmaceutical manufacturer. AffyXell is a joint venture established in January 2020 by Daewoong Pharmaceutical and Avacta, developing the next generation of cell and gene therapies based on mesenchymal stem cells which incorporate Affimer immunotherapies. This new ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters